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Introduction: Computed tomography (CT) of chest is increasingly used as a
sensitive measure of early lung disease in CF children; showing correlation between
Brody-II CT scores and pulmonary function tests (PFTs) with greatest correlation
seen in lung clearance index (LCI) [1,2]. This relationship has yet to be established
during infancy.
Aim: To explore the relationship between PFTs and CT scans in NBS CF infants.
Method: CF infants underwent PFTs at ~1 year old, followed by volumetric
inspiratory and expiratory high resolution CT scan of the chest under general
anaesthesia within 2 weeks of the PFTs. Scans were anonymised and scored using
Brody-II.
Results: Of 62 CF infants tested, 16% (10/61) had elevated LCI, 15% (9/60)
elevated plethysmographic lung volume and 17% (10/59) diminished forced ex-
piratory volume or ﬂow. Bronchial dilatation present in 8% (5/62) of the HRCT
scans. Although gas trapping was seen in 24% (15/62), only 2% had signiﬁcant
involvement. Total CT score was not correlated with LCI or forced expiratory
volumes and ﬂows. Gas trapping sub-score revealed signiﬁcant but weak correlation
with LCI (Spearman correlation, R = 0.3).
Conclusions: In early infancy, few abnormalities were detected by CT with minimal
correlation to lung function. Further study is required to establish the evidence for
routine use of CT in monitoring early lung disease in CF infants diagnosed through
NBS.
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Objectives: It can be difﬁcult to demonstrate that drugs targeting CFTR beneﬁt
patients with mild disease. If FEV1 is in the normal range, it may be of limited
value. A more sensitive test such as LCI may be useful.
Methods: This Phase 2, randomized, double-blind, placebo-controlled, multicenter,
crossover study evaluated the effect of ivacaftor on LCI derived from multibreath
washout of SF6 using an Innocor device. Subjects were 6 years with the G551D-
CFTR mutation, FEV1 >90% predicted, and LCI >7.4 (the upper limit of normal).
Ivacaftor 150mg or placebo was administered q12h for two 4-week periods with a
4-week washout in between. Enrollment is complete (n = 21); results reported here
are from the interim analysis of the ﬁrst 7 subjects to have completed both periods.
Results: Mean (SD) age was 14.0 (8.6) years. Mean (SD) baseline LCI was 9.2
(1.9). The treatment effect of ivacaftor for adjusted mean change from baseline
in LCI at Day 29 was −2.22 (P = 0.0097). Mean (SD) baseline FEV1 was 98.5%
predicted (6.4%). The treatment difference for the mean change from baseline in
FEV1 was 7.2% (P = 0.1264). The treatment difference for the mean change from
baseline in sweat chloride was −48.3mmol/L (P = 0.0086). 6 subjects reported
AEs in the ivacaftor period vs. 5 in the placebo period. 1 SAE was reported
(constipation).
Conclusions: Treatment with ivacaftor signiﬁcantly improved LCI. Trends were
seen for FEV1, but these were not statistically signiﬁcant. These preliminary results
suggest that LCI is more sensitive than FEV1 in detecting treatment effect among
CF subjects with minimal lung disease and should be considered as an endpoint in
future trials.
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